Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
Bob Chandler retired from his role as cofounder and principal of Chandler Chicco Companies and president of InVentiv Health Communications in 2014.
Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money
I'm not suggesting that colleges become vocational schools. But don't you think they should also help young people prepare for the life they're going to be living?
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients
This event will focus on the wide-ranging application of this thinking in healthcare, identify the latest trends in achieving patient engagement, and share standout examples and new insights.
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Each of this year's Influencers wields significant influence at a major health-related organization and boasts high-profile accomplishments, oftentimes ahead of the aforementioned pain-of- change curve.
Join this webinar to hear new, patient focused research from Univision and Nielsen's Hispanic Healthcare Journey study.
Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in
Mayo Clinic's CEO talks about how a trusted name in healthcare has evolved digitally and centered communications on its newsroom while retaining integrity.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
McCann Health, the 2016 Lions Health Network of the Year, and Campaign invited top marketers and visionary artists to discuss creativity during this year's Lions Health festival.
The power of hackathons is now magnified because of the power of the internet and social media, giving both patients and healthcare professionals a global platform for their voices.
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
Such intense interest in health content is a rich opportunity to engage, inform, support, and motivate key customer constituencies.
It is the group's first acquisition since it was assembled in February under CEO Karen van Bergen.
The Siri for Seniors took the top prize at the second MM&M Shark Tank for its annual healthcare conference.
Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.
Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?
Learn about Merck's new innovation team as well as read profiles of 9 other teams at companies such as Google and Johnson & Johnson.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Publicis Health formalizes new name, promotes 3 execs
- Digital IDs become focus as drugmakers seek to track doctors' behavior online